Literature DB >> 30393969

Non-uraemic calciphylaxis successfully treated with pamidronate infusion.

David H Truong1, Marcus M Riedhammer2, Kathya Zinszer3.   

Abstract

Calciphylaxis is a rare and potentially fatal disease that affects the subcutaneous layer of the skin. It is a calcific vasculopathy induced by a systemic process that causes occlusion of small blood vessels. The mortality rate for individuals diagnosed with calciphylaxis is estimated between 52% and 81% with sepsis being the leading cause of death. Uraemic calciphylaxis and its known effective treatments are well documented in the literature. Unfortunately, there is no known effective treatment for non-uraemic calciphylaxis. Most of the current treatments for non-uraemic calciphylaxis are derived from uraemic calciphylaxis treatment protocols. We report a case of a 75-year-old female with calciphylaxis on the right lower extremity who was successfully treated with four pamidronate infusions in addition to local wound care. This case represents a non-uraemic calciphylaxis wound successfully treated with pamidronate infusions and standard wound care, and suggests that IV pamidronate can be an effective treatment option.
© 2018 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  calcific arteriolopathy; leg ulcer; non-healing wound; sodium thiosulphate; vascular calcifications

Mesh:

Substances:

Year:  2018        PMID: 30393969      PMCID: PMC7948727          DOI: 10.1111/iwj.13019

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  28 in total

1.  Cutaneous molt induced by calciphylaxis in the rat.

Authors:  H SELYE; G GENTILE; P PRIORESCHI
Journal:  Science       Date:  1961-12-08       Impact factor: 47.728

2.  Calciphylaxis and the cardiometabolic syndrome.

Authors:  Melvin R Hayden; Lisa G Kolb; Ramesh Khanna
Journal:  J Cardiometab Syndr       Date:  2006

Review 3.  Fatal childhood calciphylaxis in a 10-year-old and literature review.

Authors:  Jing Feng; Mona Gohara; Rossitza Lazova; Richard J Antaya
Journal:  Pediatr Dermatol       Date:  2006 May-Jun       Impact factor: 1.588

4.  Net-like pattern of calcification on plain soft-tissue radiographs in patients with calciphylaxis.

Authors:  Eugenia Shmidt; Naveen S Murthy; John M Knudsen; Roger H Weenig; M Amanda Jacobs; Autumn M Starnes; Mark D P Davis
Journal:  J Am Acad Dermatol       Date:  2012-07-28       Impact factor: 11.527

5.  Successful treatment of calciphylaxis with pamidronate.

Authors:  Stefan Schliep; Gerold Schuler; Franklin Kiesewetter
Journal:  Eur J Dermatol       Date:  2008-08-08       Impact factor: 3.328

6.  Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates.

Authors:  Takaaki Hanafusa; Yuji Yamaguchi; Mamori Tani; Noriko Umegaki; Yukari Nishimura; Ichiro Katayama
Journal:  J Am Acad Dermatol       Date:  2007-12       Impact factor: 11.527

7.  Calciphylaxis in Patients With Preserved Kidney Function.

Authors:  Natallia Maroz; Samer Mohandes; Halle Field; Zlata Kabakov; Richard Simman
Journal:  J Am Coll Clin Wound Spec       Date:  2015-08-07

8.  Sodium thiosulfate in the treatment of non-uremic calciphylaxis.

Authors:  Matthew S Ning; Kathryn M Dahir; Emily H Castellanos; Laura Y McGirt
Journal:  J Dermatol       Date:  2013-05-10       Impact factor: 4.005

9.  Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis.

Authors:  Colette B Raymond; Lori D Wazny
Journal:  Am J Health Syst Pharm       Date:  2008-08-01       Impact factor: 2.637

10.  Acral gangrene as a presentation of non-uremic calciphylaxis.

Authors:  Muhammad Hammadah; Shruti Chaturvedi; Jennifer Jue; Andrew Blake Buletko; Mohammed Qintar; Mohammed Eid Madmani; Prashant Sharma
Journal:  Avicenna J Med       Date:  2013-10
View more
  3 in total

1.  Non-uraemic calciphylaxis successfully treated with pamidronate infusion.

Authors:  David H Truong; Marcus M Riedhammer; Kathya Zinszer
Journal:  Int Wound J       Date:  2018-11-04       Impact factor: 3.315

2.  Topical cannabis-based medicines - A novel paradigm and treatment for non-uremic calciphylaxis leg ulcers: An open label trial.

Authors:  Vincent Maida; Runjie B Shi; Francesco G T Fazzari; Lydia Zomparelli
Journal:  Int Wound J       Date:  2020-09-02       Impact factor: 3.315

3.  Calciphylaxis in end-stage kidney disease: outcome data from the United Kingdom Calciphylaxis Study.

Authors:  Rajkumar Chinnadurai; Abby Huckle; Janet Hegarty; Philip A Kalra; Smeeta Sinha
Journal:  J Nephrol       Date:  2021-02-06       Impact factor: 3.902

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.